Fundraising Fox

Aravax

Melbourne, AU · 20 employees on LinkedIn · 4 known investors

Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies. Founded on technology from Alfred Health and Monash University, it operates internationally with offices in Melbourne, Australia and Oxford, UK.

BiotechHealthtechMedical Devices

Founders & leadership

SPSara Prickett
Sara PrickettCo-founder

Investors · 4

Novartis Venture Fund✓ verifiedBasel · $5M – $25M
Tenmile✓ verified
Breakthrough Victoria✓ verifiedMelbourne
UniSeed Pty Ltd.reportedBrisbane · $165K – $330K

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy - BioSpacebiospace.com · Aug 2026Biotech Aravax raises $66m for peanut allergy curebusinessnewsaustralia.com · Jan 2024Promising Food Allergy Treatment from Aravax Receives $12 Million Investment - SnackSafely.comsnacksafely.com · Jan 2024Peanut allergy treatment startup raises $66m in funding — Capital Briefcapitalbrief.com · Jan 2024Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapyaravax.com.au · Jan 2024Aravax commences Phase 2 in peanut allergy with $20m Series B from Brandon Capital and Tenmilearavax.com.au · Dec 2022

Frequently asked questions

What does Aravax do?
Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies. Founded on technology from Alfred Health and Monash University, it operates internationally with offices in Melbourne, Australia and Oxford, UK.
Who founded Aravax?
Aravax was founded by Sara Prickett.
Who are Aravax's investors?
Aravax's investors include Novartis Venture Fund, Tenmile, Breakthrough Victoria, UniSeed Pty Ltd..
Where is Aravax headquartered?
Aravax is headquartered in Melbourne, AU.